Literature DB >> 10408258

Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells.

K Nitta1, K Uchida, N Kimata, K Honda, H Kobayashi, A Kawashima, W Yumura, H Nihei.   

Abstract

We designed the present study to address the question of whether recombinant human erythropoietin stimulates DNA synthesis and vascular endothelial growth factor (VEGF) secretion in vitro using cultured bovine glomerular endothelial cells (GENs). Recombinant human erythropoietin dose-dependently stimulated the proliferation of GENs in culture, and this proliferative effect was inhibited by 1 microg/ml anti-VEGF antiserum. The increase in VEGF concentrations in the supernatants containing 10 U/ml rHuEpo was abolished by incubation with 10 microg/ml of anti-human rHuEPO antiserum, 0.2 microg/ml actinomycin D or 10 microg/ml cycloheximide. Taken together, rHuEpo stimulates GEN proliferation in vitro and VEGF release from these cells is associated with stimulation of RNA-dependent DNA and protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408258     DOI: 10.1016/s0014-2999(99)00281-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.

Authors:  Amy M Meadowcroft; Borut Cizman; Louis Holdstock; Nandita Biswas; Brendan M Johnson; Delyth Jones; A Kaldun Nossuli; John J Lepore; Michael Aarup; Alexander R Cobitz
Journal:  Clin Kidney J       Date:  2018-03-19

2.  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.

Authors:  Louis Holdstock; Amy M Meadowcroft; Rayma Maier; Brendan M Johnson; Delyth Jones; Anjay Rastogi; Steven Zeig; John J Lepore; Alexander R Cobitz
Journal:  J Am Soc Nephrol       Date:  2015-10-22       Impact factor: 10.121

3.  Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.

Authors:  Zhangning Fu; Xiaodong Geng; Kun Chi; Chengcheng Song; Di Wu; Chao Liu; Quan Hong
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.